Treatment Outcomes of Third-line Antiretroviral Regimens in HIV-infected Thai Adolescents

The Pediatric Infectious Disease Journal
Wasana PrasitsuebsaiHIV-NAT 113 Study Group

Abstract

Efficacy and safety data of third-line antiretroviral (ARV) regimens in adolescents are limited. This study enrolled HIV-infected Thais who were treated with third-line regimens consisting of darunavir/ritonavir (DRV/r), etravirine (ETR), tipranavir/ritonavir or raltegravir. Fifty-four adolescents 2-17 years of age were enrolled from 8 sites and followed for 48 weeks. Reasons for switch were second-line failure (n = 44) and toxicity to second-line regimens (n = 10). At switching to third-line ARV, the median age (interquartile range) was 14.3 (12.4-15.4) years. Genotypes at time of second-line failure (n = 44) were M184V (77%), ≥4 thymidine analogue mutations (25%), non-nucleoside reverse transcriptase inhibitor-resistant associated mutation (RAM) (80%), ETR-RAM score ≥4 (14%), any lopinavir-RAM (59%) and ≥1 major DRV-RAM (41%). The third-line regimens had a median of 4 (min-max, 4-6) drugs and included ETR/DRV/r (43%), DRV/r (33%), ETR (17%), tipranavir/ritonavir (2%) or raltegravir/DRV/r/ (4%). The median CD4 (interquartile range) increased from 16% (12-21) at third-line switch to 21% (18-25) and 410 (172-682) to 607 (428-742) cells/mm at 48 weeks (P < 0.001). HIV RNA declined from 3.9 (2.9-4.9) to 1.6 (1.6-3.0) log10 copies/...Continue Reading

References

Aug 6, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Arkaitz ImazEsteban Ribera
Apr 19, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Margaret P RhoadsE G Hermione Lyall
Oct 27, 2011·AIDS Research and Therapy·Torsak BunupuradahJintanat Ananworanich
Nov 28, 2012·PloS One·Brian C ZanoniMargaret E Feeney
Oct 23, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sharon NachmanUNKNOWN International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team
Mar 29, 2014·Journal of the International Association of Providers of AIDS Care·Olukemi Osinusi-AdekanmbiAnthony Amoroso
Jun 6, 2014·AIDS Patient Care and STDs·Jintana IntasanUNKNOWN PREDICT Study Group
Aug 3, 2014·Global Health Action·Samsuddin KhanPetros Isaakidis
Sep 16, 2014·PloS One·Carina CesarUNKNOWN Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet)
Apr 25, 2015·AIDS Research and Therapy·Weerawat ManosuthiUNKNOWN Adults and Adolescents Committee of the Thai National HIV Guidelines Working Group
Jul 23, 2015·AIDS Research and Human Retroviruses·Wasana PrasitsuebsaiAnnette H Sohn
Sep 26, 2015·Journal of the Pediatric Infectious Diseases Society·Paola CostenaroCarlo Giaquinto
Oct 27, 2016·AIDS·Wolfgang StöhrUNKNOWN Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team

❮ Previous
Next ❯

Citations

Mar 2, 2019·Current Infectious Disease Reports·J Nuttall, V Pillay
Jul 30, 2020·Journal of the International AIDS Society·Gabriela PattenUNKNOWN IeDEA

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.